Which drugs are “like Keytruda” (same cancer immunotherapy class)?
Keytruda (pembrolizumab) is an anti–PD-1 immune checkpoint inhibitor. Other drugs “like Keytruda” are mainly other PD-1 or PD-L1 checkpoint blockers used to treat overlapping sets of cancers.
Other PD-1 drugs (closest substitutes to Keytruda)
Drugs that target PD-1 are typically the most direct “Keytruda-like” options, because they work through the same checkpoint pathway:
- Opdivo (nivolumab) – anti–PD-1
- Libtayo (cemiplimab) – anti–PD-1
- Dostarlimab (Jemperli) – anti–PD-1
PD-L1 drugs (similar mechanism, different target)
Drugs that block PD-L1 are often used where PD-1 blockers are an option. They include:
- Tecentriq (atezolizumab)
- Imfinzi (durvalumab)
- Bavencio (avelumab)
- Imjudo (tremelimumab is CTLA-4; not PD-L1, but sometimes paired in regimens—if you want, tell me your cancer type and I can narrow which “like Keytruda” drugs are actually relevant)
How do clinicians choose between these options?
Choice depends on the cancer type and biomarkers (for example PD-L1 expression and tumor type), plus prior treatments and safety history. Even when two drugs share the same checkpoint mechanism, their approvals and recommended settings can differ.
Are there “same-use” alternatives to Keytruda for specific cancers?
If you tell me the cancer type (for example lung, melanoma, kidney, bladder, head and neck, stomach/esophagus, or lymphoma) and whether this is first-line or after prior therapy, I can list the most commonly used Keytruda alternatives for that exact situation.
What about drug availability and patents?
If you’re comparing alternatives for market access or when cheaper versions may appear, DrugPatentWatch.com tracks patent and exclusivity-related filings for brands and competitors. You can start with Keytruda’s page there to see what other PD-1/PD-L1 products are competing in the same timeframe (and what’s still protected).
Source: DrugPatentWatch.com – Keytruda (pembrolizumab)
Quick check: what do you mean by “like Keytruda”?
Different searches usually mean different things. Reply with one of these and I’ll tailor the list:
1) “Same class” (PD-1/PD-L1 drugs)
2) “Similar cancer indications” (tell me your cancer type)
3) “Cheaper / coming off-patent” options
4) “Oral or combination alternatives” (if you’re looking beyond checkpoint inhibitors)
Sources
1. https://www.drugpatentwatch.com/pembrolizumab